Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries

remdesivir
Gilead Sciences will work with five manufacturers to boost production of remdesivir. (Gilead)

After scoring an early authorization for its COVID-19 therapy remdesivir, Gilead Sciences has been on the hunt for manufacturing partners to help boost production. Through a series of licensing agreements with generics makers, Gilead has taken the first steps to build that network. 

Gilead signed nonexclusive licensing agreements with five generic drug makers operating in India and Pakistan to produce COVID-19 therapy remdesivir for 127 countries, the drugmaker said. 

Gilead will work with Cipla, Mylan, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences to manufacture the drug primarily for low- and lower-middle income countries. The list also includes higher-income countries "that face significant obstacles to healthcare access," Gilead said.

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

Under the agreements, Gilead will share its manufacturing know-how with the five companies to help them gear up remdesivir production. Each company will be allowed to set the price for its own generic version of the drug.

The licensed drugmakers won't pay royalties to Gilead until the World Health Organization calls off the novel coronavirus public health emergency or until another therapy for COVID-19 is approved, Gilead said. Pfizer, which is developing a candidate with partner BioNTech, said Monday that it was evaluating the need for outsourcing production of some its drug portfolio to make way for a massive COVID-19 vaccine effort in the coming months.

Remdesivir scored an FDA emergency use nod earlier this month to treat severely ill COVID-19 patients. 

RELATED: Gilead, working on its own remdesivir ramp-up, scouts licensing partners for global production

Last week, Gilead said it was scouting for external partners to boost its ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022.

Remdesivir manufacturing relies on “scarce” raw materials that command their own “lengthy” production timelines, Gilead has said. Moving forward, coordination on producing the drug will be “critical,” the drugmaker says.

Gilead also said last week it was in talks to license the drug to the Medicines Patent Pool, an organization that could then sublicense it to generics companies for distribution in emerging markets. Gilead has already licensed several other medicines to the group, MPP’s website shows.

RELATED: Regeneron CEO: Manufacturing not up to snuff for COVID-19 vaccines, therapies

Gilead's push to bolster its remdesivir manufacturing comes as drugmakers across the board scramble to scale up production for their own possible therapies and vaccines.

Sunday, Regeneron CEO Len Schleifer told CNN's "State of the Union" that manufacturing capacity to fulfill global demand for a COVID-19 treatment or vaccine is "limited"––a troubling assessment from one of the drugmakers leading the fight for an answer to the novel coronavirus pandemic.

"If there's something we have to learn from this pandemic so that when COVID-21 or -25 or -32 comes along, we need a little bit more capacity already in place so that we can get it to everybody,” Schleifer said.

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

Lonza is on deck to help manufacture AstraZeneca's COVID-fighting antibody duo at its Portsmouth, New Hampshire site.